Quizartinib (AC220): Selective FLT3 Inhibition for Acute Myeloid Leukemia Research

Executive Summary: Quizartinib (AC220) is a second-generation, highly selective FLT3 inhibitor for acute myeloid leukemia (AML) research, showing sub-5 nM IC₅₀ against both FLT3-ITD and FLT3-WT (APExBIO, product page). It achieves approximately 10-fold selectivity for FLT3 over related kinases such as PDGFRα, KIT, RET, and CSF-1R (Shin et al. 2023). Quizartinib blocks FLT3 autophosphorylation, halting downstream signaling crucial for AML cell proliferation and survival. In vivo, oral dosing at 1 mg/kg inhibits FLT3 activity and extends survival in mouse xenograft models. Resistance mutations in FLT3 can arise, underscoring the ongoing need for robust signaling pathway analysis in AML research (Shin et al. 2023).

Biological Rationale

FLT3 (FMS-like tyrosine kinase 3) is a type III receptor tyrosine kinase. Mutations in FLT3, particularly internal tandem duplications (ITD), occur in approximately 30% of AML cases. These mutations confer constitutive kinase activity, driving uncontrolled proliferation of leukemic blasts and correlating with poor prognosis (Shin et al. 2023). FLT3 activation triggers downstream signaling via the JAK/STAT, MAPK, and PI3K/AKT pathways. These pathways are critical for cell survival and expansion in both AML and blast-phase chronic myeloid leukemia (BP-CML). Targeted inhibition of FLT3 has become a validated research strategy for dissecting leukemogenic circuits and for preclinical evaluation of candidate therapeutics. The clinical challenge of TKI resistance—due to kinase domain mutations or activation of compensatory pathways—reinforces the importance of selective FLT3 inhibitors in research workflows (Shin et al. 2023).

Mechanism of Action of Quizartinib (AC220)

Quizartinib (AC220) is a potent, orally bioavailable tyrosine kinase inhibitor. It selectively targets FLT3 by binding to its ATP-binding pocket, thereby blocking kinase autophosphorylation and downstream signaling. The compound exhibits IC₅₀ values of 1.1 nM for FLT3-ITD and 4.2 nM for FLT3-WT in cell-based assays (APExBIO). Its selectivity profile shows at least a ten-fold preference for FLT3 over kinases such as PDGFRα, PDGFRβ, KIT, RET, and CSF-1R. Quizartinib rapidly inhibits FLT3 autophosphorylation, leading to apoptosis and growth arrest in FLT3-dependent AML cell lines (e.g., MV4-11). In vivo, it achieves significant target engagement and tumor regression in FLT3-driven mouse xenograft models at doses as low as 1 mg/kg. The drug’s pharmacokinetics are characterized by a peak plasma concentration (C_max) of 3.8 μM within 2 hours post-oral dosing. Its solubility is ≥28.03 mg/mL in DMSO but negligible in ethanol or water, necessitating careful solvent selection for experimental use. Resistance can develop through secondary FLT3 mutations, underscoring the value of Quizartinib for resistance mechanism studies (Shin et al. 2023).

Evidence & Benchmarks

• Quizartinib inhibits FLT3-ITD autophosphorylation with an IC₅₀ of 1.1 nM in MV4-11 AML cells (APExBIO).
• Demonstrates >10-fold selectivity for FLT3 over PDGFRα, KIT, RET, and CSF-1R, minimizing off-target kinase inhibition (Shin et al. 2023).
• Inhibits proliferation of AML cell lines (MV4-11, RS4;11) at low nanomolar concentrations (related review).
• Oral administration at 1 mg/kg in mouse xenograft models achieves FLT3 pathway inhibition, extends survival, and leads to complete tumor regression in some cases (Shin et al. 2023).
• Pharmacokinetic profiling reveals C_max of 3.8 μM at 2h post-dose, supporting robust plasma exposure (APExBIO).
• Emergence of FLT3 resistance mutations is observed in clinical and preclinical AML models, making Quizartinib a reference tool for resistance studies (Shin et al. 2023).

Earlier articles, such as this review, focus on the molecular targeting profile of Quizartinib; the present article extends this by integrating recent translational findings on resistance pathways and workflow adoption. The meta-analysis at FLT-3.com details in vitro and in vivo benchmarks, while this article updates with new pharmacokinetic and selectivity data. For hands-on laboratory protocols and troubleshooting, see this guide; the current text clarifies long-term storage and solubility limits for reproducibility.

Applications, Limits & Misconceptions

Quizartinib (AC220) is optimized for research use in acute myeloid leukemia, especially for dissecting FLT3 signaling and resistance mechanisms. Its high potency and selectivity make it suitable for cell-based assays, biochemical kinase panels, and in vivo mouse xenograft studies. The compound is not intended for diagnostic or therapeutic use in humans. It is supplied as a solid and must be stored at -20°C. Solutions in DMSO are stable short-term but not recommended for long-term storage; fresh preparation is advised prior to experiments (APExBIO).

Common Pitfalls or Misconceptions

• Quizartinib is not effective against all forms of AML—its activity is limited in FLT3-negative or non-ITD mutated cases.
• It does not inhibit compensatory pathways (e.g., downstream RAS/MAPK, PI3K) unless FLT3 is the dominant driver.
• Not recommended for use in ethanol or water due to poor solubility; DMSO is the preferred solvent.
• Not suitable for diagnostic or therapeutic applications in clinical settings.
• Resistance mutations in FLT3 can abrogate Quizartinib efficacy; these must be screened for in research models.

Workflow Integration & Parameters

For in vitro kinase assays, dissolve Quizartinib at ≥28.03 mg/mL in DMSO. Recommended working concentrations for cell-based assays range from 0.1 nM to 100 nM, with optimal inhibition observed at low nanomolar levels in FLT3-ITD cells. For in vivo studies, oral administration at 1 mg/kg achieves robust FLT3 blockade. Store the solid compound at -20°C and avoid prolonged storage of solutions. For resistance studies, combine with BCR::ABL1 TKIs or other agents to model signal redundancy and pathway crosstalk, as highlighted in recent studies (Shin et al. 2023).

Conclusion & Outlook

Quizartinib (AC220), as provided by APExBIO (A5793 kit), is a validated, highly selective FLT3 inhibitor for AML research. Its robust potency, favorable bioavailability, and well-characterized resistance profile make it a cornerstone tool for dissecting FLT3-driven leukemogenesis and evaluating novel therapeutic strategies. Ongoing research into resistance mechanisms and pathway redundancy will further expand Quizartinib’s utility in both AML and refractory CML model systems. For researchers requiring reproducibility and specificity in FLT3 pathway interrogation, Quizartinib remains a benchmark reagent.